For Research Use Only, Not For Human Consumption or Use

Premium research-grade peptide. Purity > 99%. Double lab tested. USA based testing.

Retatrutide

Price range: $89.00 through $249.00

🔬 For Research Use Only  |  📦 Discreet Packaging  |  🧪 99%+ Purity Verified
SKU: RETA Category:

Retatrutide product description — Triple hormone receptor agonist peptide

Research Peptide · Triple Agonist · LY3437943

Retatrutide

An investigational once-weekly triple hormone receptor agonist activating GLP-1, GIP, and Glucagon receptors simultaneously. The highest weight reduction reported in the incretin class. Purity >99% · Double lab tested.

5 mg · 10 mg · 20 mg
Research Use Only
$89 – $249

Regulatory status

Not yet FDA approved. Under active Phase 3 clinical investigation (TRIUMPH program). NDA submission expected after 2026 trial readouts — earliest plausible approval window is 2027.
Developer
Eli Lilly · Code: LY3437943
Program
TRIUMPH Phase 3
Phase 3 readouts
Through 2026
Dosing
Once-weekly subcutaneous

Mechanism of action — triple receptor

GLP-1 receptor
Insulin & appetite control
Stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite centrally — the same broad effects as semaglutide.
GIP receptor
Augmented glucose control
Amplifies glucose-dependent insulin release; also influences adipose tissue and central pathways relevant to body weight regulation.
Glucagon receptor
Energy expenditure & lipolysis
Raises basal energy expenditure and promotes lipolysis — the key differentiator from dual agonists like tirzepatide, driving superior weight loss.

Clinical trial evidence

Phase 2 — Obesity (NEJM, 2023)
Participants on 12 mg weekly dose at 48 weeks — the highest weight reduction reported for any agent in the GLP-1 class at the time.
24.2% body weight loss
12 mg weekly · 48 weeks
TRIUMPH-4 — Knee Osteoarthritis (Dec 2025)
Phase 3 readout in adults with obesity/overweight and knee osteoarthritis. Showed substantial reductions in both body weight and osteoarthritis pain scores.
~28.7% weight loss
Significant pain reduction
Phase 3 — Type 2 Diabetes (Mar 2026)
Demonstrated significant reductions in HbA1c and body weight in adults with type 2 diabetes.
HbA1c reduction
Significant weight loss
Ongoing TRIUMPH studies
Active trials in obstructive sleep apnea, chronic low back pain, cardiovascular & renal outcomes, and metabolic liver disease (MASLD).

Adverse effects & safety

Adverse-effect profile is broadly consistent with the GLP-1 class — gastrointestinal symptoms predominate, particularly during dose escalation: nausea, vomiting, diarrhea, and constipation.

Notable signal: dysesthesia (skin tingling, sensitivity, altered tactile sensation) — reported in ~21% of TRIUMPH-4 participants on the 12 mg dose. Most events were mild; further characterization is ongoing in Phase 3. Cardiovascular and pancreatic safety will be evaluated through the full Phase 3 dataset.
Size

10mg, 20mg, 5mg

Reviews

There are no reviews yet.

Be the first to review “Retatrutide”

Your email address will not be published. Required fields are marked *

All Vital Tides peptides are manufactured under strict quality control and independently verified for purity and molecular identity. For research and laboratory use only. Not for human consumption.
Certificate of Analysis available upon request.
Standard Shipping (3-5 Business Days): $14.99  |  2-Day Shipping: $24.99 — Cold-chain packaging included with 2-day shipping.

Age Verification

By clicking "I Agree", you confirm that you are 18 years of age or older and acknowledge that all Vital Tides products are for research purposes only.

By clicking "I Agree", you are acknowledging that all products are for research purposes only and are not for human consumption, not for medical or diagnostic use, and are not intended to diagnose, treat, cure, or prevent any disease.

Logo